IPOs and Secondaries
IPOs and Secondaries Articles
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.
Published:
Citizens Financial Group has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Published:
First Data Corp. has filed paperwork with the U.S. Securities & Exchange Commission (SEC) to conduct its initial public offering (IPO).
Published:
NEP Group has filed with the U.S. Securities and Exchange Commission (SEC) to price its initial public offering (IPO).
Published:
vTv Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Software company SunGard has filed with the U.S. Securities and Exchange Commission for its initial public offering (IPO).
Published:
ThinkstockThe initial public offering (IPO) calendar for this week lists six companies with plans to enter the public market. Of the eight companies that had scheduled IPOs last week, seven...
Published:
Last Updated:
ThinkstockIt is a bull market, stocks are close to all-time highs, and many investors still are in love with chasing initial public offerings (IPOs). Still, some IPOs turn out to not be that hot....
Published:
Rapid7 announced the pricing for its initial public offering (IPO) and then entered the market Friday morning.
Published:
Great Western Bancorp has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Published:
Rapid7, a provider of security data and analytics solutions, is preparing to set the price for its initial public offering.
Published:
Ollie's Bargain Outlet entered the market Thursday with a bang. Shares debuted at well above the pricing and rose 44%.
Published:
NantKwest has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
UTAC Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
ProNai Therapeutics has set the price for its initial public offering (IPO) that values it up to roughly $158 million.
Published: